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Abstract
Background: Growing concerns about safety of ART on human gametes, embryos, clinical outcomes and long-
term health of offspring require improved methods of risk assessment to provide functionally relevant assays for
quality control testing and pre-clinical studies prior to clinical implementation. The one-cell mouse embryo assay
(MEA) is the most widely used for development and quality testing of human ART products; however, concerns
exist due to the insensitivity/variability of this bioassay which lacks standardization and involves subjective analysis
by morphology alone rather than functional analysis of the developing embryos. We hypothesized that
improvements to MEA by the use of functional molecular biomarkers could enhance sensitivity and improve
detection of suboptimal materials/conditions.
Results: Fresh one-cell transgenic mouse embryos with green fluorescent protein (GFP) expression driven by
Pou6f1 or Cdx2 control elements were harvested and cultured to blastocysts in varied test and control conditions to
compare assessment by standard morphology alone versus the added dynamic expression of GFP for screening
and selection of critical raw materials and detection of suboptimal culture conditions. Transgenic mouse embryos
expressing functionally relevant biomarkers of normal early embryo development can be used to monitor the
developmental impact of culture conditions.
Conclusions: This novel approach provides a superior MEA that is more meaningful and sensitive for detection of
embryotoxicity than morphological assessment alone.
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Background
Early detection of anomalies in developing embryos is
crucial to successful outcomes in assisted reproduction
technology (ART). The one-cell mouse embryo assay
(MEA) is routinely performed as the quality control bio-
assay to assess the conditions to which human embryos
will be subjected [1–4].
The in vitro development of one-cell mouse zygotes to
the blastocyst stage by 96 h is closely monitored for nor-
mal morphology and sufficient formation of expanded/
hatching blastocysts (at least 80 % to pass the test) to
evaluate the biocompatibility and quality of culture
conditions and materials. However, concerns exist due
to the insensitivity of MEA to toxic materials and
suboptimal culture conditions [5, 6]. Additionally, this
bioassay lacks standardization and involves subjective
analysis of morphology alone. The 80 % blastocyst
rate passing specification for MEA is set according to
accepted trending in the industry and is not based on
actual statistical criteria.
Growing concerns about detrimental effects of ART
on human gametes, embryos, clinical outcomes and
long-term health of offspring require improved methods
of risk assessment to provide scientifically robust and
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functionally relevant assays for pre-clinical studies prior
to clinical implementation [7–10]. Several attempts have
been made to enhance the sensitivity of the MEA, in-
cluding culturing embryos in smaller groups, reducing
the volume of culture medium, removing protein com-
ponents from the medium, and counting total nuclei per
embryo at 96 h for a quantitative comparison of blasto-
cyst grade [11–13]. Given that the quality of embryos
varies from harvest to harvest, it is desirable to make im-
provements to the MEA by use of functional molecular
biomarkers to enhance sensitivity to suboptimal materials
and conditions and, in turn, increase the safety and suc-
cessful outcome of in vitro fertilization.
Evidence of dynamic expression and functional profiles
of transcription factors during embryogenesis is accumu-
lating. Early developmental genes are known to be differ-
entially expressed starting at the two-cell stage, around
the time when gene expression profiles switch from the
maternal pattern to the zygotic pattern (zygotic gene ac-
tivation, or ZGA), continuing through the blastocyst
stage and exhibiting localized expression patterns in the
developing embryo. Pou5f1 (previously known as Oct4)
is a well-described transcription factor known for its role
as a pluripotency regulator [14–17]. Pou5f is highly
expressed starting at the 4- to 8-cell stage after initiation
of ZGA and throughout embryonic development. Caudal
type homeobox 2 (Cdx2) is another early developmental
gene that signals the initial stages of cell lineage differen-
tiation in pre-implantation mouse embryos. Cdx2 ex-
pression starts around E3.5 when asymmetric cell
divisions in 8- & 16-cell embryos occur, and is tightly re-
stricted to the trophectoderm (TE) [18, 19]. POU5F1
and CDX2 are initially co-expressed in pre-implantation
mouse embryos and form a complex for the reciprocal
repression of their target genes in embryonic stem cells
[20]. During progression from morula to blastocyst,
coordinated repression of Pou5f1 by CDX2 takes place.
A regulatory complex formed with CDX2 suppresses ex-
pression of Pou5f1 in the TE, while the expression of
Pou5f1 is maintained within the ICM in the absence of
CDX2, thereby establishing localized expression patterns
of POU5F1 and CDX2 [21].
The advantages of using mouse embryos for quality
control of ART media and materials cannot be ignored.
Transgenic mouse technology may provide further ad-
vantages by allowing us to generate embryos expressing
fluorescent reporter proteins under the control of regu-
latory elements of early developmental markers, such as
POU5F1 and CDX2, for a more sensitive and biologically
relevant detection of embryotoxicity.
In this study, we used transgenic mouse embryos ex-
pressing green fluorescent protein under control of
Pou5f1 (POU5F1-GFP) or Cdx2 (CDX2-GFP) regulatory
elements and monitored developing embryos with GFP
expression patterns in addition to the standard morph-
ology assessment criteria, as a more sensitive means to
distinguish suboptimal from optimal embryo culture
conditions. We refer to this combination of expression
patterns and morphological assessment as the Genetic
Mouse Embryo Assay (MEGA™). We found that a high
level of fluorescence intensity observed at 48 h (early
fluorescence intensity, or EFI) is predictive for the suc-
cessful development of blastocysts at 96 h. We also
show that MEGA outperforms MEA by combining the
state of zygotic gene expression and cell lineage dif-
ferentiation with morphological assessment, and can
be applied as a stand-alone in vitro model system of
embryonic development to determine biocompatibility
of ART media and materials.
Methods
Preparation and collection of mouse embryos
Mice were purchased from the Jackson Laboratory (Jax,
Bar Harbor, ME) and maintained by the UC-Irvine Trans-
genic Mouse Facility (TMF). Mouse strain B6C3F1/J was
used in studies for standard MEA (no transgene). Mouse
strain B6; CBA-Tg (Pou5f1-EGFP) 2Mnn/J carries a
randomly-integrated transgene that expresses enhanced
GFP (EGFP) under control of the Pou5f promoter and dis-
tal enhancer. Mouse strain STOCK-Cdx2tm1Yxz/J has the
GFP coding sequence inserted in-frame, downstream of
the third exon of Cdx2, by homologous recombination.
Mice of either strain were mated with B6D2F1/J mice.
The TMF collected zygotes from females the morning
after mating were set up, examined each zygote for evi-
dence of fertilization, and supplied all fertilized one-cell
embryos in FHM (Millipore, USA, catalog # MR-024-D)
to Irvine Scientific. All procedures were conducted with
the approval of UCI’s Institutional Animal Care & Use
Committee, in accordance with all relevant institutional
and federal regulations.
Prior to mating, embryo donor female mice were
superovulated by IP injection with 5 IUs of pregnant
mare serum gonadotropin (PMSG, NHPP, Torrance,
CA) between noon and 2 PM, followed 46–48 h later by
an IP injection of 5 IUs of recombinant human chorionic
gonadotropin (hCG, NHPP, Torrance, CA), to stimulate
the release of oocytes and synchronize estrus cycles.
Matings (1 female per male) were set up immediately
following the hCG injection. Mating performance of
the studs was assessed by recording the presence or
absence of a mating plug in each female the next day,
just prior to harvesting. Stud males that failed to plug
3 consecutive times were replaced, and all studs were
replaced at 10–12 months of age.
Embryo donors were euthanized by CO2 inhalation.
Oviducts were removed and placed in FHM containing
0.3 mg/ml hyaluronidase (Sigma, St. Louis, MO, catalog
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# H3884). Cumulus-oocyte complexes were released
from the oviducts by tearing open the ampulla and ex-
posed to hyaluronidase just long enough to separate cu-
mulus cells from the oocytes (<5 min). The oocytes were
then passed through several washes of FHM to remove
hyaluronidase, and observed on an inverted microscope
with DIC optics. Oocytes were considered to be fertil-
ized if they had normal morphology and had exactly
2 pronuclei.
Embryo culture
Fertilized, freshly harvested one-cell mouse embryos
(with or without transgene) were cultured in Continuous
Single Culture Medium (CSCM) with 5 mg/mL human
serum albumin (HSA) with oil overlay (Irvine Scientific).
Embryo culture was conducted using either micro-drops
(3–4 embryos/20 μL drop) overlayed with 7 mL mineral
oil on 60 mm petri dishes (Falcon, #35-1007) or micro-
wells (one embryo/10 μL/well or 10 embryos/10 μL/well)
overlayed with 9 mL mineral oil on 72-micro-well plates
(VWR #82050-710) and incubated at 37 °C, 5 % CO2 in
air (21 % O2) for 96 h. Culture medium in dishes/plates
was pre-equilibrated overnight in the 37 °C incubator
with 5.0 – 5.5 % CO2 in air (21 % O2) prior to addition
of freshly harvested and washed one-cell embryos.
Freshly harvested one-cell mouse embryos were pooled,
washed three times in pre-equilibrated culture medium
and randomly distributed into the respective test condi-
tions, then returned to the incubated at 37 °C, 5 % CO2
in air (21 % O2) for up to 96 h with no medium change
(uninterrupted). Development rates were evaluated at
48 h and/or 96 h.
Standard mouse embryo assay
The sensitivity of different culture set up methods was
initially evaluated using CSCM-C that was adulterated
with addition of formaldehyde (Sigma), which is typically
used for proficiency testing, at 0 to 7× concentration
(1 × = 9.3 × 10−5% formaldehyde) and set up in parallel
using micro-drop or micro-well assays (as described
above). Fresh one-cell mouse embryos (B6D2F1 ×
B6C3F1, n = 33 per condition) were used for this assay.
Blastocyst development rates (expanded and hatching
blastocysts) were observed and recorded at 96 h.
Genetic mouse embryo assay (MEGA™)
Sensitivity of MEGA to suboptimal conditions was deter-
mined through experiments that were conducted using a
dose response of previously identified detrimental (PID)
oil vs. control oil conditions (Irvine Scientific, 2 lots oil,
n = 30 to 90 embryos per condition, 3 experiments). A
case study was then conducted in one experiment,
which consisted of screening 5 lots of human serum
albumin (HSA) in parallel (including control and test lots)
to evaluate variability between lots (n = 43 embryos per
treatment condition using micro-drop method).
Embryos were graded for morphology at 48 h (as < 8-
cell or ≥ 8-cell stage) and fluorescence intensity (termed
early fluorescence intensity or EFI) of POU5F1-GFP ex-
pression was observed with fluorescent microscope
(Olympus IX51, 480nmEx/535/550nmEm) and scored
on a scale of 0–3 at 48 h. The percentages of em-
bryos with a low EFI of 0 to 1 (EFI 0–1) or a high
EFI of 2 to 3 (EFI 2–3) were calculated and these
values were compared to the blastocyst development rates
of the respective conditions to determine correlation be-
tween high EFI with % blastocyst at 96 h. Embryos were
also graded at 96 h as ≤ blastocysts (up to blastocyst with
small blastocoel cavity), or expanded (>50 % blastocoel
cavity, large and well-expanded) and hatching blastocysts
(with a herniation in the zona pellucida (ZP) or hatched)
and calculated as a percent of total embryos analyzed.
Similar experiments were conducted using the mice trans-
genic for Cdx2-GFP. The ICM-specific expression of
POU5F1-GFP and TE-specific expression of CDX2-GFP
at the advanced blastocyst stages were examined at 96 h
for further verification of normal blastocyst development.
Two-way ANOVA followed by Dunnett’s multiple
comparisons test was performed using GraphPad Prism
version 6.05 (GraphPad Software, www.graphpad.com).
Results
To determine the impact of culture methodology on
assay sensitivity, we examined two embryo culture meth-
ods—micro-well and micro-drop methods—for relative
sensitivity in detecting toxicity of materials and subopti-
mal culture conditions. Adulterated media containing
formaldehyde (from 1 to 7× concentrated, where 1 × =
9.3 × 10−5 %) was used to culture fresh one-cell mouse
embryos (B6D2F1 × B6C3F1) with micro-drop or
micro-well in parallel (Fig. 1). A passing development
rate of at least 80 % at 96 h was observed with 2 fold
concentrated (2×) formaldehyde with micro-drops (3–4
embryos/20 μL drop) while embryos cultured in micro-
wells (10 embryos/10 μL/well) tolerated up to 5× formal-
dehyde, demonstrating that use of the micro-drop method
is more sensitive to toxicity than the micro-well method.
The micro-drop method was therefore used throughout
the rest of this study, unless otherwise noted.
In order to further improve the sensitivity of the
MEA, we integrated mouse embryos with a reporter
protein linked to an endogenously expressed early devel-
opmental regulator. We hypothesized that Pou5f1-GFP
zygotes with 2 pronuclei (2PN) produced by mating
transgenic mice strain B6; CBA-Tg (Pou5f1-EGFP)
2Mnn/J with B6D2F1/J can be cultured in vitro and
monitored at 48 h and 96 h to assess their development
(Fig. 2). Consistent with previous reports, we observed
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expression of POU5F1-GFP in blastomeres of cleavage
stage embryos as early as 48 h, which was subsequently
down regulated and localized to the ICM [14, 15] of
expanded blastocysts (Fig. 2a). Some Pou5f1-GFP em-
bryos failed to fully develop into blastocysts or did
not reach the expanded blastocyst stage at 96 h. Notably,
POU5F1-GFP was expressed to varying degrees among
embryos at 48 h, and those embryos showing a high EFI
were shown to correlate with successive development to
the advanced blastocyst stages (expanded/hatching), while
embryos with a low EFI (Fig. 1a & b, arrows) exhibited
arrested or delayed development.
One-cell (2PN) transgenic CDX2-GFP zygotes were
also obtained, cultured in control medium and observed
for expression and development up to 96 h (Fig. 2c).
CDX2-GFP expression was localized to the TE in ex-
panded blastocysts at the 96 h time point, confirming
normal blastocyst development [21]. However, overall
weak fluorescent intensity at 48 h (~8-cell cleavage)
made scoring difficult, and the CDX2-GFP embryos did
not exhibit a strong correlation between EFI and on-
going blastocyst development, therefore subsequent
studies were limited to POU5F1-GFP embryos.
Next we monitored and tracked Pou5f1-GFP embryo
development and POU5F1-GFP expression up to 96 h
by culturing the embryos in control medium in micro-
well plates (one embryo/10 μl/well) to determine if there
was a correlation between early Pou5f1-GFP expression
and embryonic development (Fig. 3). POU5F1-GFP ex-
pression at 48 h (as shown Fig. 2a) was used to score
embryos on a scale of 0 to 3 as early fluorescence inten-
sity (EFI) and grouped into low EFI (EFI 0–1) or high
EFI (EFI 2–3) (Fig. 3, 48 h). Successive development of
Pou5f1-GFP embryos were monitored and graded at
96 h with localization pattern of POU5F1-GFP and
grouped according to their morphological stage: expanded
and hatching/hatched blastocysts (E/H, yellow) or ≤ blasto-
cysts (white). Notably, 92.9 % of the embryos that exhibited
a high EFI at 48 h (39.3 % of total embryos tested, n = 107)
Fig. 1 Detection of toxicity by two mouse embryo culture methods.
To determine sensitivity of two culture methods—micro-drop (red)
or micro-well (black), adulterated media containing formaldehyde
(from 1 to 7× concentrated, where 1 × = 9.3 × 10−5%) were used in
parallel to culture fresh one-cell mouse embryos (B6D2F1 × B6C3F1).
Development of mouse embryos was monitored by morphology at
96 h after uninterrupted culture for % blastocyst rates (including
expanded and hatching/hatched, n = 33)
Fig. 2 POU5F1-GFP and CDX2-GFP expression during early embryogenesis in vitro. Development of 2PN zygotes in control medium was monitored
for morphology and expression up to 96 h. POU5F1-GFP expression at 48 h (a) was used to score embryos on a scale of 0 to 3 for early fluorescence
intensity (EFI): low EFI (score 0–1, arrow) or high EFI (score 2–3,*). Three embryos exhibited high EFI of POU5F1-GFP at 48 h (a) and
subsequently developed into expanded and hatching blastocysts (b) with expression localized to the ICM (*), compared to one embryo
(arrow) with low EFI which failed to develop to the blastocyst stage. Similarly, CDX2-GFP embryos that developed to the expanded/hatching
blastocyst stages at 96 h express the normal localization pattern of CDX2 in the TE (c*)
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developed into E/H blastocysts by 96 h while 64.6 % of the
embryos with low EFI at 48 h (60.7 % of total embryos) de-
veloped into E/H blastocysts by 96 h. Overall, the total %
Blastocyst (E/H) development by morphology alone was
75.7 % (n = 81) at 96 h.
Pou5f1-GFP embryos cultured in micro-drops over-
layed with control and suboptimal (10 % PID) mineral
oil were used in a double-blinded assessment of MEA
(morphology alone) and MEGA (EFI of POU5F1-GFP
expression) to determine the level of sensitivity for de-
tecting suboptimal conditions (Fig. 4). Double-blinded
assessment of embryos was conducted at 48 h by
morphology (reaching at least 8-cell stage) and by EFI
(high EFI). At 48 h morphological development to ≥8
cells stage of embryos in control and suboptimal condi-
tions were comparable at 65.9 % and 63.3 %, respect-
ively, whereas 89.8 % of control embryos expressed high
EFI compared to only 33.3 % for embryos under subopti-
mal conditions, suggesting that POU5F1-GFP expression
is a more sensitive indicator of normal embryo develop-
ment. Subsequent blastocyst development rates at 96 h
(graded by morphology and localized expression of
POU5F1-GFP) were 86.4 % for control and 30.0 % for
suboptimal condition, results similar to those for high
EFI rates at 48 h, further demonstrating the predictive
value of EFI at 48 h and sensitivity of POU5F1-GFP ex-
pression over morphology alone.
To assess the responsiveness of MEGA as a stand-
alone bioassay, Pou5f1-GFP embryos cultured by micro-
drop assay were evaluated in a dose–response to PID oil
(0–15 %) and evaluated for development (morphology)
and expression at 48 h and 96 h (Fig. 5). At 48 h toxicity
was shown at 10 % PID oil by morphology, but EFI was
more sensitive in detecting toxicity at 7.5 %, supporting
previous findings. The blastocyst development rates at
96 h (which included localization of expression) showed
toxicity starting at the 10 % PID concentration.
Additional experiments were conducted with Pou5f1-
GFP embryos under suboptimal conditions of a dose–re-
sponse with PID oil. Pou5f1-GFP embryos from three
different harvests were cultured in vitro under adulter-
ated mineral oil (5 %, 10 %, or 15 % PID oil) and graded
by MEA and MEGA. Pou5f1-GFP embryos showed
dose–response of development and POU5F1-GFP ex-
pression and were reproducible with the concentrations
tested (Fig. 6). At 48 h, the % high EFI was significantly
lower for MEGA embryos in 15 % PID oil condition
(p < 0.05) and at 96 h the % blastocyst rates for both
MEA and MEGA were significantly lower for 10 %















Fig. 3 Micro-well culturing POU5F1-GFP expressing embryos. 2PN
zygotes (n = 107) expressing Pou5f1-GFP were cultured individually in
control medium with micro-well method (one embryo/10 μL/well)
and monitored for morphology and GFP expression up to 96 h.
Developmental progress of individual embryos was shown as a
hierarchical diagram. Pou5f1-GFP embryos were evaluated at 48 h and
grouped as EFI 0–1 (score 0–1) or EFI 2–3 (score 2–3). Their successive
development was monitored and graded at 96 h with detection of
POU5F1-GFP and divided into two groups: expanded and hatching/
hatched blastocysts (E/H, yellow) or≤ blastocysts (white) Fig. 4 Double-blinded assessment of Pou5f1-GFP embryo development.
Control and suboptimal (10 % PID oil) culture conditions were tested
with micro-drop method for effect on Pou5f1-GFP embryo development
and gene expression. Pou5f1-GFP embryos were evaluated at 48 h for
morphology (≥8 cell) and expression (MEGA, high EFI 2–3), and subse-
quently assessed at 96 h for blastocyst development with localized ex-
pression of POU5F1-GFP, shown as % Embryos
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To further demonstrate the sensitivity of MEGA to
embryo culture conditions, a case study of various lots
of HSA raw material was conducted using Pou5f1-GFP
embryos (n = 43 per condition) evaluating morphology
and POU5F1-GFP expression at 48 and 96 h. The results
in Table 1 show no difference by 48 h morphology
(at least 95 % of embryos reached at least 8 cell stage), but
high EFI suggests 2 lots of HSA (lots A and D) may be
suboptimal. The subsequent blastocyst rates (E/H = ex-
panded and hatching) at 96 h were lowest for the two cor-
responding lots of HSA reaching 72.7 % (failing) and
83.7 % for HSA-A and HSA-D, respectively, compared to
the other lots which resulted in >85 % expanded/hatching
blastocysts, demonstrating the predictive value and sensi-
tivity of EFI over morphology alone. Taken together, these
data demonstrate that MEGA may have greater sensitivity
than standard MEA in addition to an early predictive
value of suboptimal conditions at 48 h which are
confirmed by subsequent rates of normal embryo de-
velopment at 96 h.
Fig. 5 Oil dose–response. Pou5f1-GFP embryos (n = 20 per condition)
were cultured under PID oil (0, 5, 7.5, 10, or 15 %) and evaluated for
embryo development/expression at 48 h (8-cell or EFI) and 96 h
(E/H blastocysts)
Fig. 6 Oil dose–response and sensitivity of MEGA for detection
of suboptimal conditions. The sensitivity of Pou5f1-GFP embryos
to culture conditions was further assessed with various doses of
PID oil. Pou5f1-GFP embryos cultured under oil overlays containing 0
(control), 5, 10, or 15 % PID oil were evaluated for embryo development/
expression at 48 h (8-cell or EFI) and 96 h (E/H) (3 experiments). Statistical
analysis: 2-way ANOVA with multiple comparisons. *p< 0.05, **p< 0.005,
****p< 0.0001. Error bars: mean ± SEM
Table 1 HSA Case study
Culture
conditions
48 h 96 h
≥8-cell morphology High EFI aE/H Blastocysts
HSA-A 95.5 86.4 72.7
HSA-B 95.3 90.7 86.0
HSA-C 97.7 93.0 93.0
HSA-D 97.7 81.4 83.7
HSA-E 95.3 95.3 95.3
aE/H, expanded and hatching blastocysts
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Discussion
The culture method used for the mouse embryo assay
can impact the sensitivity of detecting toxic substances,
as demonstrated by use of the micro-drop assay. Possible
explanations for the enhanced sensitivity of the micro-
drop assay include: 1) availability of less autocrine/para-
crine factors in the microenvironment as a result of
lower embryo/volume ratio and separation of embryos
resting on the flat surface under micro-drop (compared
to the micro-well assay with conical shape, closer prox-
imity of embryos, higher embryo/culture volume ratio
and availability of more autocrine/paracrine factors
which may benefit embryo development and mask envir-
onmental toxicity), 2) the relative surface area exposure
of oil (and potential toxins therein) to embryo culture
medium is greater in micro-drop method.
By using the more sensitive micro-drop culture
method and employing transgenic mouse embryos ex-
pressing POU5F1-GFP, we demonstrated MEGA to be
an improved bioassay with increased sensitivity to toxic
materials and suboptimal culture conditions, with early
predictive values of development, using early fluores-
cence intensity (EFI) at 48 h, in addition to standard
morphological evaluation of blastocysts at 96 h.
Furthermore, unlike the standard MEA, a fluorescence-
based bioassay can be assessed quantitatively and stan-
dardized for consistency. Our findings suggest MEGA
can be applied as a stand-alone in vitro quality-control
system. The ability to observe the state of zygotic
gene expression and obtain more detailed morpho-
logical assessments (e.g., by monitoring normal/expected
localization of expression) adds versatility to the bioassay.
Timely expression of selected early development regulator
Pou5f1 in transgenic mouse embryos was correlated
with embryonic development to blastocysts and provided
sensitive screening for suboptimal culture conditions
and materials.
It should be noted that while CDX2-GFP was expressed
properly in TE of blastocysts, where TE development
starts around E3.5 (or 60 h after fertilization), the corre-
sponding EFI at 48 h could not be accurately scored be-
cause CDX2-GFP expression started at a time point later
than 48 h. To address this issue, we plan to evaluate other
fluorescent reporters and perform time-lapse fluorescence
microscopy on individual embryos. Larger studies will
need to be conducted with key markers to build sufficient
data for statistical analysis to define the quantitative ac-
ceptance criteria for practical application.
Additional enhancements to the MEGA protocol
might be achieved by combining two or more differ-
ent colors of fluorescent reporters in a single mouse
strain, to allow simultaneous monitoring of more than
one early development regulator or cell lineage. Fur-
thermore, we hypothesize that sensitivity of MEGA
can be enhanced by integrating other genes which are
active during pre-implantation and potentially im-
pacted by culture conditions or ART materials.
Conclusions
These studies demonstrate a proof of principle that
transgenic mouse embryos expressing POU5F1-GFP, a
functionally relevant biomarkers of normal early devel-
opment, can be used in combination with morphological
assessment as an enhanced assay (MEGA®) to detect
embryotoxicity and identify the developmental impact of
materials and culture conditions. Our data suggest that
the addition of functional molecular biomarkers to
morphology can improve quality control assessment of
biocompatibility of ART media and materials prior to
clinical implementation and thereby better address po-
tential impact to ongoing embryo development, ART
outcomes and risks to the long-term health of offspring.
Further studies are required to define comprehensive
molecular indicators of early development that may
benefit human reproductive studies including ART, gam-
ete development, and stem cell research.
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